Page last updated: 2024-11-13

yqa14

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

YQA14: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46195374
SCHEMBL ID2315158
MeSH IDM0573371

Synonyms (4)

Synonym
SCHEMBL2315158
1221408-42-9
yqa14
AKOS040749826

Research Excerpts

Overview

YQA14 is a novel D3R antagonist that has exhibited pharmacotherapeutic efficacy in reducing cocaine and amphetamine reward and relapse to drug seeking in mice.

ExcerptReferenceRelevance
"YQA14 is a novel D3R antagonist that has exhibited pharmacotherapeutic efficacy in reducing cocaine and amphetamine reward and relapse to drug seeking in mice."( Selective dopamine D3 receptor antagonist YQA14 inhibits morphine-induced behavioral sensitization in wild type, but not in dopamine D3 receptor knockout mice.
Hu, G; Hu, RR; Jing, M; Li, J; Lv, Y; Song, R; Wu, N; Zhao, TY, 2019
)
1.5

Treatment

ExcerptReferenceRelevance
"Pretreatment with YQA14 significantly and dose-dependently attenuated cocaine-enhanced BSR."( Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats.
Bi, GH; Gardner, EL; Li, J; Song, R; Xi, ZX; Yang, RF; Zhang, HY, 2014
)
1.02

Bioavailability

ExcerptReferenceRelevance
" Liver microsomal clearances and in vivo clearances were moderate in rats and dogs consistent with the moderate bioavailability observed in both species."( Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
Li, J; Li, Z; Liu, F; Lu, C; Xiong, S; Yang, C; Zhang, Z; Zhuang, X, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]